Therapy escalation following an elevated hba1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis

Ying Xie; Jannah Baker; Tamara Young; Min Jun; Louisa Sukkar; Anna Campain; Amy Kang; Alan Cass; Ji Hu; David Peiris; Carol Pollock; Germaine Wong; Sophia Zoungas; Kris Rogers; Meg Jardine; Carinna Hockham; on behalf of the EXTEND45 Steering Committee

doi:10.2337/dc20-0269

Therapy escalation following an elevated hba_1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis

Ying Xie, Jannah Baker, Tamara Young, Min Jun, Louisa Sukkar, Anna Campain, Amy Kang, Alan Cass, Ji Hu, David Peiris, Carol Pollock, Germaine Wong, Sophia Zoungas, Kris Rogers, Meg Jardine, Carinna Hockham, on behalf of the EXTEND45 Steering Committee

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Letter › Research › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	e185-e187
Number of pages	3
Journal	Diabetes Care
Volume	43
Issue number	11
DOIs	https://doi.org/10.2337/dc20-0269
Publication status	Published - Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/dc20-0269

Cite this

Xie, Y., Baker, J., Young, T., Jun, M., Sukkar, L., Campain, A., Kang, A., Cass, A., Hu, J., Peiris, D., Pollock, C., Wong, G., Zoungas, S., Rogers, K., Jardine, M., Hockham, C., & on behalf of the EXTEND45 Steering Committee (2020). Therapy escalation following an elevated hba_1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis. Diabetes Care, 43(11), e185-e187. https://doi.org/10.2337/dc20-0269

@article{d14659016d4144b2a5ca1bbd81a8bb53,

title = "Therapy escalation following an elevated hba1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis",

author = "Ying Xie and Jannah Baker and Tamara Young and Min Jun and Louisa Sukkar and Anna Campain and Amy Kang and Alan Cass and Ji Hu and David Peiris and Carol Pollock and Germaine Wong and Sophia Zoungas and Kris Rogers and Meg Jardine and Carinna Hockham and {on behalf of the EXTEND45 Steering Committee}",

note = "Funding Information: The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW and partners the National Heart Foundation of Australia (NSW Division), NSW Ministry of Health, NSW Government Family and Community Services-Ageing, Carers, and the Disability Council NSW, and the Australian Red Cross Blood Service. The authors thank the many thousands of people participating in the 45 and Up Study. In addition, the authors thank Services Australia (formerly Department of Human Services) for their supply of MBS and PBS data and the private pathology companies who have contributed their data to this study. Data linkage was performed by the Sax Institute and the Centre for Health Record Linkage (CHeReL) (https://www.cherel.org.au). Funding and Duality of Interest. The EX-TEND45 Study is in part funded through peer-reviewed, unconditional grants, including an NSW Cardiovascular Research Network Development Project Grant from the National Heart Foundation of Australia (award no. 100720), a seeding GENESIS grant supported by Roche Products Pty Ltd. (grant no. FR-MIR-0095), and a Rebecca L. Cooper Grant (grant no. REB002). In addition, the EXTEND45 Study has received unconditional research grants from Eli Lilly (Australia) Pty Ltd. (grant no. PO4100294024), Merck Sharp & Dohme (Australia) Pty Ltd. (grant no. MSD_EXTEND45), and Amgen (Australia) Pty Ltd. (grant no. Amgen01). Y.X. received funding from the National Natural Science Foundation of China (grant no. 81670742) and Suzhou Municipal Science and Technology Bureau (grant ref. szxk201804) to conduct this research project. M.Ju. has received unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. C.P. is the current chair of the following: Kidney Health Australia, NSW Bureau of Health Infor-mation, and the NSW Cardiovascular Research Network; is a member of the international advisory board for AstraZeneca; is a member of local advisory boards for Vifor, Merck Sharp & Dohme, Boehringer Ingelheim, and Otsuka; serves on the scientific advisory board of Phar-maxis; has received travel and accommodation support from Amgen, AstraZeneca, and Roche; and has received speaker support from Amgen, AstraZeneca, Novartis, and Vifor. S.Z. has partic-ipated in the advisory board, expert committees, or educational meetings for Boehringer Ingelheim, Eli Lilly, Sanofi, Servier, AstraZeneca, NovoNordisk, and Merck Sharp & Dohme on behalf of Monash University, with no direct financial compensation. M.Ja. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Pro-gram Career Development Fellowship; is respon-sible for research projects that have received unrestricted funding from Gambro, Baxter, CSL Behring, Amgen, Eli Lilly, and Merck; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim, and Vifor; and has spoken at scientific meetings sponsored by Janssen, Am-gen, and Roche, with any consultancy, honoraria, or travel support paid to her institution. No other potential conflicts of interest relevant to this article were reported. Funding Information: Acknowledgments. The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW and partners the National Heart Foundation of Australia (NSW Division), NSW Ministry of Health, NSW Government Family and Community ServicesdAgeing, Carers, and the Disability Council NSW, and the Australian Red Cross Blood Service. The authors thank the many thousands of people participating in the 45 and Up Study. In addition, the authors thank Services Australia (formerly Department of Human Services) for their supply of MBS and PBS data and the private pathology companies who have contributed their data to this study. Data linkage was performed by the Sax Institute and the Centre for Health Record Linkage (CHeReL) (https://www.cherel.org.au). Funding and Duality of Interest. The EX TEND45 Study is in part funded through peer-reviewed, unconditional grants, including an NSW Cardiovascular Research Network Development Project Grant from the National Heart Foundation of Australia (award no. 100720), a seeding GENESIS grant supported by Roche Products Pty Ltd. (grant no. FR-MIR-0095), and a Rebecca L. Cooper Grant (grant no. REB002). In addition, the EXTEND45 Study has received unconditional research grants from Eli Lilly (Australia) Pty Ltd. (grant no. PO4100294024), Merck Sharp & Dohme (Australia) Pty Ltd. (grant no. MSD_EXTEND45), and Amgen (Australia) Pty Ltd. (grant no. Amgen01). Y.X. received funding from the National Natural Science Foundation of China (grant no. 81670742) and Suzhou Municipal Science and Technology Bureau (grant ref. szxk201804) to conduct this research project. M.Ju. has received unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. C.P. is the current chair of the following: Kidney Health Australia, NSW Bureau of Health Information, and the NSW Cardiovascular Research Network; is a member of the international advisory board for AstraZeneca; is a member of local advisory boards for Vifor, Merck Sharp & Dohme, Boehringer Ingelheim, and Otsuka; serves on the scientific advisory board of Phar-maxis; has received travel and accommodation support from Amgen, AstraZeneca, and Roche; and has received speaker support from Amgen, AstraZeneca, Novartis, and Vifor. S.Z. has participated in the advisory board, expert committees, oreducationalmeetingsforBoehringerIngelheim, EliLilly,Sanofi,Servier,AstraZeneca,NovoNordisk, and Merck Sharp & Dohme on behalf of Monash University, with no direct financial compensation. M.Ja. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship; is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL Behring, Amgen, Eli Lilly, and Merck; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim, and Vifor; and has spoken at scientific meetings sponsored by Janssen, Am-gen, and Roche, with any consultancy, honoraria, or travel support paid to her institution. No other potential conflicts of interest relevant to this article were reported. Data Availability. The data sets generated during this study are not publicly available because of ethical restrictions. However, upon reasonable request, and with permission of the relevant data custodians, data may be accessed through the Secure Unified Research Environment (SURE). The appropriate steps for becoming a SURE user and accessing SURE will need to be undertaken. Readers can visit the relevant page on the 45 and Up Study website for more information. Author Contributions. Y.X., M.Ja., and C.H. were responsible for the study concept and design. Y.X. and C.H. drafted the manuscript. All authors gave critical revision of the manuscript for important intellectual content and interpreted the data. J.B. and K.R. provided statistical analysis. M.Ja. and C.H. supervised the manuscript. C.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

doi = "10.2337/dc20-0269",

language = "English",

volume = "43",

pages = "e185--e187",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "11",

}

Xie, Y, Baker, J, Young, T, Jun, M, Sukkar, L, Campain, A, Kang, A, Cass, A, Hu, J, Peiris, D, Pollock, C, Wong, G, Zoungas, S, Rogers, K, Jardine, M, Hockham, C & on behalf of the EXTEND45 Steering Committee 2020, 'Therapy escalation following an elevated hba_1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis', Diabetes Care, vol. 43, no. 11, pp. e185-e187. https://doi.org/10.2337/dc20-0269

TY - JOUR

T1 - Therapy escalation following an elevated hba1c in adults aged 45 years and older living with diabetes in Australia

T2 - A real-world observational analysis

AU - Xie, Ying

AU - Baker, Jannah

AU - Young, Tamara

AU - Jun, Min

AU - Sukkar, Louisa

AU - Campain, Anna

AU - Kang, Amy

AU - Cass, Alan

AU - Hu, Ji

AU - Peiris, David

AU - Pollock, Carol

AU - Wong, Germaine

AU - Zoungas, Sophia

AU - Rogers, Kris

AU - Jardine, Meg

AU - Hockham, Carinna

AU - on behalf of the EXTEND45 Steering Committee

N1 - Funding Information: The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW and partners the National Heart Foundation of Australia (NSW Division), NSW Ministry of Health, NSW Government Family and Community Services-Ageing, Carers, and the Disability Council NSW, and the Australian Red Cross Blood Service. The authors thank the many thousands of people participating in the 45 and Up Study. In addition, the authors thank Services Australia (formerly Department of Human Services) for their supply of MBS and PBS data and the private pathology companies who have contributed their data to this study. Data linkage was performed by the Sax Institute and the Centre for Health Record Linkage (CHeReL) (https://www.cherel.org.au). Funding and Duality of Interest. The EX-TEND45 Study is in part funded through peer-reviewed, unconditional grants, including an NSW Cardiovascular Research Network Development Project Grant from the National Heart Foundation of Australia (award no. 100720), a seeding GENESIS grant supported by Roche Products Pty Ltd. (grant no. FR-MIR-0095), and a Rebecca L. Cooper Grant (grant no. REB002). In addition, the EXTEND45 Study has received unconditional research grants from Eli Lilly (Australia) Pty Ltd. (grant no. PO4100294024), Merck Sharp & Dohme (Australia) Pty Ltd. (grant no. MSD_EXTEND45), and Amgen (Australia) Pty Ltd. (grant no. Amgen01). Y.X. received funding from the National Natural Science Foundation of China (grant no. 81670742) and Suzhou Municipal Science and Technology Bureau (grant ref. szxk201804) to conduct this research project. M.Ju. has received unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. C.P. is the current chair of the following: Kidney Health Australia, NSW Bureau of Health Infor-mation, and the NSW Cardiovascular Research Network; is a member of the international advisory board for AstraZeneca; is a member of local advisory boards for Vifor, Merck Sharp & Dohme, Boehringer Ingelheim, and Otsuka; serves on the scientific advisory board of Phar-maxis; has received travel and accommodation support from Amgen, AstraZeneca, and Roche; and has received speaker support from Amgen, AstraZeneca, Novartis, and Vifor. S.Z. has partic-ipated in the advisory board, expert committees, or educational meetings for Boehringer Ingelheim, Eli Lilly, Sanofi, Servier, AstraZeneca, NovoNordisk, and Merck Sharp & Dohme on behalf of Monash University, with no direct financial compensation. M.Ja. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Pro-gram Career Development Fellowship; is respon-sible for research projects that have received unrestricted funding from Gambro, Baxter, CSL Behring, Amgen, Eli Lilly, and Merck; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim, and Vifor; and has spoken at scientific meetings sponsored by Janssen, Am-gen, and Roche, with any consultancy, honoraria, or travel support paid to her institution. No other potential conflicts of interest relevant to this article were reported. Funding Information: Acknowledgments. The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW and partners the National Heart Foundation of Australia (NSW Division), NSW Ministry of Health, NSW Government Family and Community ServicesdAgeing, Carers, and the Disability Council NSW, and the Australian Red Cross Blood Service. The authors thank the many thousands of people participating in the 45 and Up Study. In addition, the authors thank Services Australia (formerly Department of Human Services) for their supply of MBS and PBS data and the private pathology companies who have contributed their data to this study. Data linkage was performed by the Sax Institute and the Centre for Health Record Linkage (CHeReL) (https://www.cherel.org.au). Funding and Duality of Interest. The EX TEND45 Study is in part funded through peer-reviewed, unconditional grants, including an NSW Cardiovascular Research Network Development Project Grant from the National Heart Foundation of Australia (award no. 100720), a seeding GENESIS grant supported by Roche Products Pty Ltd. (grant no. FR-MIR-0095), and a Rebecca L. Cooper Grant (grant no. REB002). In addition, the EXTEND45 Study has received unconditional research grants from Eli Lilly (Australia) Pty Ltd. (grant no. PO4100294024), Merck Sharp & Dohme (Australia) Pty Ltd. (grant no. MSD_EXTEND45), and Amgen (Australia) Pty Ltd. (grant no. Amgen01). Y.X. received funding from the National Natural Science Foundation of China (grant no. 81670742) and Suzhou Municipal Science and Technology Bureau (grant ref. szxk201804) to conduct this research project. M.Ju. has received unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. C.P. is the current chair of the following: Kidney Health Australia, NSW Bureau of Health Information, and the NSW Cardiovascular Research Network; is a member of the international advisory board for AstraZeneca; is a member of local advisory boards for Vifor, Merck Sharp & Dohme, Boehringer Ingelheim, and Otsuka; serves on the scientific advisory board of Phar-maxis; has received travel and accommodation support from Amgen, AstraZeneca, and Roche; and has received speaker support from Amgen, AstraZeneca, Novartis, and Vifor. S.Z. has participated in the advisory board, expert committees, oreducationalmeetingsforBoehringerIngelheim, EliLilly,Sanofi,Servier,AstraZeneca,NovoNordisk, and Merck Sharp & Dohme on behalf of Monash University, with no direct financial compensation. M.Ja. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship; is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL Behring, Amgen, Eli Lilly, and Merck; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim, and Vifor; and has spoken at scientific meetings sponsored by Janssen, Am-gen, and Roche, with any consultancy, honoraria, or travel support paid to her institution. No other potential conflicts of interest relevant to this article were reported. Data Availability. The data sets generated during this study are not publicly available because of ethical restrictions. However, upon reasonable request, and with permission of the relevant data custodians, data may be accessed through the Secure Unified Research Environment (SURE). The appropriate steps for becoming a SURE user and accessing SURE will need to be undertaken. Readers can visit the relevant page on the 45 and Up Study website for more information. Author Contributions. Y.X., M.Ja., and C.H. were responsible for the study concept and design. Y.X. and C.H. drafted the manuscript. All authors gave critical revision of the manuscript for important intellectual content and interpreted the data. J.B. and K.R. provided statistical analysis. M.Ja. and C.H. supervised the manuscript. C.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85093875402&partnerID=8YFLogxK

U2 - 10.2337/dc20-0269

DO - 10.2337/dc20-0269

M3 - Letter

C2 - 32928956

AN - SCOPUS:85093875402

SN - 0149-5992

VL - 43

SP - e185-e187

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -

Therapy escalation following an elevated hba1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis

UN SDGs

Access to Document

Other files and links

Cite this

Therapy escalation following an elevated hba_1c in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis